keyword
MENU ▼
Read by QxMD icon Read
search

Apremilast

keyword
https://www.readbyqxmd.com/read/29750443/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-update-short-version-part-1-systemic-treatment
#1
Alexander Nast, Lasse Amelunxen, Matthias Augustin, Wolf-Henning Boehncke, Corinna Dressler, Matthew Gaskins, Peter Härle, Bernd Hoffstadt, Joachim Klaus, Joachim Koza, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Berthold Rzany, Martin Schlaeger, Gerhard Schmid-Ott, Michael Sebastian, Ralph von Kiedrowski, Tobias Weberschock
The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process. The first section of this short version of the guideline covers systemic treatment options considered relevant by the expert panel and approved in Germany at the time of the consensus conference (acitretin, adalimumab, apremilast, cyclosporine, etanercept, fumaric acid esters, infliximab, methotrexate, secukinumab and ustekinumab)...
May 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29730885/adverse-events-associated-with-apremilast-use-and-withdrawal-for-psoriasis-in-a-real-world-setting
#2
Erica B Lee, Mina Amin, Alexander Egeberg, Jashin J Wu
Apremilast, a phosphodiesterase-4 inhibitor, is an oral therapy for treatment of psoriasis. Its safety profile is favorable, with side effects including diarrhea, nausea, vomiting, depression, and weight decrease, primarily based on clinical trial data. However, limited research exists on the side effect frequency and subsequent adverse events (AEs) in real-world practice. This retrospective chart review included patients who presented to the dermatology clinic at Kaiser Permanente Los Angeles Medical Center and were treated with apremilast at any time between January 1, 2015 and January 11, 2018...
May 6, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29730366/maintenance-of-therapeutic-response-over-one-year-using-apremilast-combination-therapy-compared-to-monotherapy-for-the-treatment-of-plaque-psoriasis-a-multicenter-retrospective-study
#3
Arvin Ighani, Jorge R Georgakopoulos, Neil H Shear, Scott Walsh, Jensen Yeung
No abstract text is available yet for this article.
May 3, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29717037/the-effect-of-biologic-and-targeted-synthetic-drugs-on-work-and-productivity-related-outcomes-for-patients-with-psoriatic-arthritis-a-systematic-review
#4
Nicolas Iragorri, Mark Hofmeister, Eldon Spackman, Glen S Hazlewood
OBJECTIVE: To systematically review the effects of biologic therapies for psoriatic arthritis [secukinumab, ustekinumab, adalimumab, etanercept, certolizumab pegol (CZP), apremilast, golimumab (GOL), or infliximab (IFX)] on work productivity. METHODS: A systematic review of Medline, EMBASE, CENTRAL, and ClinicalTrials.gov was conducted to identify randomized controlled trials reporting on work productivity outcomes at the end of the placebo-controlled double-blind period...
May 1, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29619999/a-case-of-anti-laminin-%C3%AE-1-p200-pemphigoid-with-psoriasis-vulgaris-successfully-treated-with-apremilast
#5
Yuma Waki, Koji Kamiya, Mayumi Komine, Takeo Maekawa, Satoru Murata, Norito Ishii, Takashi Hashimoto, Mamitaro Ohtsuki
No abstract text is available yet for this article.
April 5, 2018: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29619856/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-psoriasis-a-network-meta-analysis
#6
April W Armstrong, Keith A Betts, James E Signorovitch, Murali Sundaram, Junlong Li, Arijit X Ganguli, Eric Q Wu
BACKGROUND: The clinical benefits of biologic therapies for moderate-to-severe psoriasis are well established, but wide variations exist in patient response. OBJECTIVES: To determine the number needed to treat (NNT) to achieve a 75% and 90% reduction in the Psoriasis Area and Severity Index (PASI-75/90) with FDA-approved agents and evaluate the incremental cost per PASI-75 or PASI-90 responder. METHODS: The relative probabilities of achieving PASI-75 and PASI-90, as well as NNTs, were estimated using a network meta-analysis...
April 23, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29605438/-apremilast-withdrawals-more-frequent-in-standard-practice-than-in-clinical-trials
#7
J-L Schmutz
No abstract text is available yet for this article.
March 28, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29588246/drug-survival-of-apremilast-for-psoriasis-in-a-real-world-setting
#8
Erica B Lee, Mina Amin, Jashin J Wu
No abstract text is available yet for this article.
March 24, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29505325/safety-of-treatment-options-for-spondyloarthritis-a-narrative-review
#9
Salvatore D'Angelo, Antonio Carriero, Michele Gilio, Francesco Ursini, Pietro Leccese, Carlo Palazzi
Spondyloarthritis (SpA) are chronic inflammatory diseases with overlapping pathogenic mechanisms and clinical features. Treatment armamentarium against SpA includes non-steroidal anti-inflammatory drugs, glucocorticoids, conventional disease-modifying antirheumatic drugs (DMARDs, including sulfasalazine, methotrexate, leflunomide, cyclosporine), targeted synthetic DMARDs (apremilast) and biological DMARDs (TNF inhibitors, anti-IL 12/23 and anti-IL-17 agents). Areas covered: A narrative review of published literature on safety profile of available SpA treatment options was performed...
May 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29488102/therapeutics-for-adult-nail-psoriasis-and-nail-lichen-planus-a-guide-for-clinicians
#10
REVIEW
Danielle R McClanahan, Joseph C English
Nail psoriasis (NP) and nail lichen planus (NLP) can be limiting, stigmatizing and difficult to treat. Dermatologists commonly treat psoriasis and lichen planus but when associated onychodystrophy is present or is an isolated finding, some develop apprehension. The goal of this review is to develop therapeutic ladders to be used as a guide for the management of NP and NLP in everyday clinical practice. Evidence-based therapies for NP are robust and range from topical treatments to conventional systemic therapies (i...
February 27, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29469962/apremilast-alters-behavioral-responses-to-ethanol-in-mice-i-reduced-consumption-and-preference
#11
Yuri A Blednov, Adriana J Da Costa, Tamara Tarbox, Olga Ponomareva, Robert O Messing, R Adron Harris
BACKGROUND: Phosphodiesterase type 4 (PDE4) inhibitors produce widespread anti-inflammatory effects and reduce ethanol (EtOH) consumption in several rodent models. These drugs are potential treatments for several diseases, including central nervous system disorders, but clinical use is limited by their emetic activity. Apremilast is a selective PDE4 inhibitor with fewer gastrointestinal side effects that is FDA-approved for the treatment of psoriasis. METHODS: We measured the acute and chronic effects of apremilast on EtOH consumption in male and female C57BL/6J mice using the continuous and intermittent 24-hour 2-bottle choice drinking models...
May 2018: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29469954/apremilast-alters-behavioral-responses-to-ethanol-in-mice-ii-increased-sedation-intoxication-and-reduced-acute-functional-tolerance
#12
Yuri A Blednov, Adriana J Da Costa, R Adron Harris, Robert O Messing
BACKGROUND: In our companion paper, we reported that the phosphodiesterase type 4 inhibitor apremilast reduced ethanol (EtOH) intake and preference in different drinking models in male and female C57BL/6J mice. In this study, we measured the effects of apremilast on other behaviors that are correlated with EtOH consumption. METHODS: The effects of apremilast (20 mg/kg) on the following behaviors were studied in male and female C57BL/6J mice: locomotor response to a novel situation; EtOH- and lithium chloride (LiCl)-induced conditioned taste aversion (CTA) to saccharin; conditioned place preference (CPP) and conditioned place avoidance (CPA) to EtOH; severity of handling-induced convulsions after EtOH administration; EtOH-induced anxiolytic-like behavior in the elevated plus maze; duration of EtOH-induced loss of righting reflex (LORR); recovery from EtOH-induced motor impairment on the rotarod; and acute functional tolerance (AFT) to EtOH's ataxic effects...
May 2018: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29462231/efficacy-and-safety-of-apremilast-in-systemic-and-biologic-naive-patients-with-moderate-plaque-psoriasis-52-week-results-of-unveil
#13
Linda Stein Gold, Jerry Bagel, Mark Lebwohl, J Mark Jackson, Rongdean Chen, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin
<p>BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL.</p> <p>METHODS: Patients with moderate plaque psoriasis (BSA 5%-10%; static Physician's Global Assessment [sPGA] score of 3 [moderate]) and naive to systemic therapies for psoriasis were randomized (2:1) to receive apremilast 30 mg twice daily or placebo for 16 weeks...
February 1, 2018: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29452303/effect-of-biologics-on-fatigue-in-psoriatic-arthritis-a-systematic-literature-review-with-meta-analysis
#14
Thomas Reygaerts, Stéphane Mitrovic, Bruno Fautrel, Laure Gossec
OBJECTIVES: Fatigue is a significant issue in psoriatic arthritis. The objective was to assess the effect of biological disease modifying antirheumatic drugs and apremilast on fatigue in psoriatic arthritis randomised controlled trials and to compare this effect with the effect in the same trials, on pain, through a systematic literature review and meta-analysis. METHODS: A systematic literature review was performed up to January 2017 in PubMed, Embase and Cochrane databases...
February 13, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29438757/comparative-effectiveness-of-targeted-immunomodulators-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis
#15
REVIEW
Anne M Loos, Shanshan Liu, Celia Segel, Daniel A Ollendorf, Steven D Pearson, Jeffrey A Linder
BACKGROUND: The comparative effectiveness of available targeted immunomodulators for moderate-to-severe psoriasis has not been evaluated. OBJECTIVE: To evaluate the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis. METHODS: Systematic literature review of placebo-controlled and head-to-head randomized trials of 8 targeted immunomodulators that evaluated clinical benefits or harm. The primary outcome was a 75% improvement on the Psoriasis Area and Severity Index...
February 10, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29432223/management-of-beh%C3%A3-et-s-disease
#16
Fatma Alibaz-Oner, Amr H Sawalha, Haner Direskeneli
PURPOSE OF REVIEW: Current treatment modalities in Behçet's disease will be summarized in light of new studies published within the last 2 years. RECENT FINDINGS: There is an increasing interest in the treatment of refractory mucocutaneous symptoms of Behçet's disease, and results were quite promising with apremilast, anakinra, and ustekinumab. Data from large case series confirmed both the efficacy and safety of tumor necrosis factor-α inhibitors for the treatment of refractory major organ manifestations such as ocular, neurologic, vascular, and gastrointestinal involvement...
May 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29400288/a-case-of-severe-pityriasis-rubra-pilaris-with-a-dramatic-response-to-apremilast
#17
Lucie Pellonnet, Fanny Beltzung, Frédéric Franck, Jacques Rouanet, Michel D'incan
No abstract text is available yet for this article.
February 1, 2018: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29388335/real-world-data-on-the-efficacy-and-safety-of-apremilast-in-patients-with-moderate-to-severe-plaque-psoriasis
#18
E Papadavid, N Rompoti, K Theodoropoulos, G Kokkalis, D Rigopoulos
BACKGROUND: Psoriasis is a chronic inflammatory skin disease, which requires long-term, safe and effective treatment. Apremilast, a small-molecule PDE4 inhibitor, has been introduced as psoriasis (and psoriatic arthritis) treatment in Europe in 2015. OBJECTIVE: We analysed and report the efficacy and safety of apremilast in the first 51 patients with psoriasis that have undergone treatment with this novel small molecule in our outpatient clinic. METHOD: Our primary endpoint was the evaluation of clinical response to apremilast according to the percentage of Psoriasis Area Severity Index (PASI) reduction (ΔPASI) at 16 weeks after treatment initiation...
February 1, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29373924/efficacy-and-safety-of-apremilast-monotherapy-for-moderate-to-severe-psoriasis-retrospective-study
#19
Arvin Ighani, Jorge R Georgakopoulos, Linda L Zhou, Scott Walsh, Neil Shear, Jensen Yeung
BACKGROUND: Apremilast is a new oral drug for the treatment of moderate to severe plaque psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety data are limited; hence, real-world outcomes are important for elucidating the full spectrum of its adverse events (AEs) and expanding generalizability of clinical trial findings. OBJECTIVE: Assess the efficacy and safety of apremilast monotherapy in real-world practice. METHODS: A retrospective chart review was conducted in 2 academic dermatology practices...
January 1, 2018: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29367871/rapid-clearance-of-erythrodermic-psoriasis-with-apremilast
#20
Evangelia Papadavid, Georgios Kokkalis, Georgios Polyderas, Konstantinos Theodoropoulos, Dimitrios Rigopoulos
Background: Apremilast is a new immunomodulatory drug, a small molecule inhibitor of PDE4, which down-regulates the expression of multiple pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin 17, interleukin 23. Main observations: We describe a case of a 54-year-old man with erythroderma in the course of psoriasis (PASI=49), with contraindications to other psoriasis therapies, in whom total clearance of skin lesions was achieved by day 20 after therapy with apremilast at a dose of 30 mg bid (ΔPASI = 100)...
December 1, 2017: Journal of Dermatological Case Reports
keyword
keyword
64665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"